INTRODUCTION: The cannabinoids nabilone (Cesamet) and dronabinol (Marinol) are indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in cancer patients who have failed to respond adequately to conventional antiemetic therapy. DISCUSSION: The endocannabinoid (CB) system interacts with numerous other systems and pharmaceutical cannabinoids target ubiquitous CB1 and CB2 receptors in the central nervous system and periphery, relieving nausea and vomiting and pain. SUMMARY: The benefits of this novel class of medications in cancer may extend beyond CINV, as indicated by data from preclinical studies and animal models.
INTRODUCTION: The cannabinoids nabilone (Cesamet) and dronabinol (Marinol) are indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in cancer patients who have failed to respond adequately to conventional antiemetic therapy. DISCUSSION: The endocannabinoid (CB) system interacts with numerous other systems and pharmaceutical cannabinoids target ubiquitous CB1 and CB2 receptors in the central nervous system and periphery, relieving nausea and vomiting and pain. SUMMARY: The benefits of this novel class of medications in cancer may extend beyond CINV, as indicated by data from preclinical studies and animal models.
Authors: Mark G Kris; Paul J Hesketh; Mark R Somerfield; Petra Feyer; Rebecca Clark-Snow; James M Koeller; Gary R Morrow; Lawrence W Chinnery; Maurice J Chesney; Richard J Gralla; Steven M Grunberg Journal: J Clin Oncol Date: 2006-05-22 Impact factor: 44.544
Authors: Sergio Poli-Bigelli; Jose Rodrigues-Pereira; Alexandra D Carides; Guoguang Julie Ma; Krista Eldridge; Anita Hipple; Judith K Evans; Kevin J Horgan; Francesca Lawson Journal: Cancer Date: 2003-06-15 Impact factor: 6.860
Authors: Lirit N Franks; Benjamin M Ford; Nikhil R Madadi; Narsimha R Penthala; Peter A Crooks; Paul L Prather Journal: Eur J Pharmacol Date: 2014-05-20 Impact factor: 4.432
Authors: Susann B Hasler; Andreas Hirt; Annette Ridolfi Luethy; Kurt K Leibundgut; Roland A Ammann Journal: Support Care Cancer Date: 2007-10-17 Impact factor: 3.603